Clinical Trials
Recipharm opens new GMP suite for clinical trial material
Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA. The suite, which represents a...
Clinical Trials
MGC Diagnostics Announces Clinical Study to Evaluate the Diagnostic Accuracy of FOT
MGC Diagnostics Corporation , a global medical technology company, today announced a new clinical study collaboration with Restech Srl to evaluate the diagnostic accuracy of the forced oscillation technique (“FOT”) to detect lung function abnormalities. Worldwide enrollment, expected to...
Clinical Trials
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration. The results across both...
Clinical Trials
Cytori Receives FDA Approval for Burn Clinical Trial Related to BARDA Contract
Cytori Therapeutics, Inc. announced that the U.S. FDA has approved an IDE for a pilot clinical trial to evaluate Cytori Cell Therapy™ in patients with thermal burn injury. This trial, named the RELIEF trial, is a...
Clinical Trials
Kiadis Pharma receives regulatory approval for next trials for ATIR101 and ATIR201
Kiadis Pharma N.V. , a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders announces that it has obtained regulatory approval from the national authority in Belgium. The FAGG,...
Clinical Trials
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML)....
Clinical Trials
LEO Pharma announces positive results from phase 2b clinical study for tralokinumab in atopic dermatitis
LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.